IL-17 is released by Th17 cells, and is also increased in sera and skin samples of SSc patients.[35] IL-17 acts as a downstream effector of IL-1 signaling and mediates increased collagen expression, thus promoting the profibrotic process in SSc. Here, IL1A is linked to systemic sclerosis.